Dr. Lal Pathlabs Limited — M&A Activity 2020

Nov 6, 2020

November 6, 2020

National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Sandra Kurla Complex Sandra (E) Mumbai - 400 051.

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001

Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please take note that pursuant to the approval of its Board, PathLabs Unifiers Private Limited ("PUPL") (a wholly owned subsidiary) has signed binding term sheets on 6 November, 2020 for the acquisitions of the business of Bindish Diagnostic Laboratory LLP ("BDL"), in Jamnagar, Gujarat on a going concern basis, for a purchase consideration not exceeding INR 40 million and equity stake of 70% in ChanRe Diagnostic Services Private Limited ("CDSPL"), in Bengaluru, Karnataka, for a purchase consideration not exceeding INR 175 million. BDL and CDSPL are engaged in the business of providing pathological diagnostic services

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in the Annexure I & II attached to this letter.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal Pathlabs Limited

Company Secretary & Legal Head

Encl.: As above

Annexure-1

Sr.No.	Particulars in respect of the Event	Details/ Information of the Event
1.	Name of the target entity, details in brief such as size,turnover etc.	Name: Bindish Diagnostic LaboratoryLLP
		Turnover:
		FY2017-18-1.73Cr.FY 2018-19-Rs. 1.9 Cr.FY 2019-20 - Rs. 3.2 Cr.
2.	Whether the acquisition would fall within related partytransaction(s) and whether the promoter/ promotergroup/ group companies have any interest in the entitybeing acquired? If yes, nature of interest and detailsthereof and whether the same is done at "arm's lenqth";	No, the transactions are not relatedparty transactions.
3.	Industry to whichthe entitv beina acquired belonqs.	Healthcare/ Diaqnostics
4.	Objects and effects of acquisition (including but notlimited to, disclosure of reasons for acquisition of targetentity,if its business is outside the main line ofbusiness of the listed entity);	Company'sTostrengthenthepresence in the state of Gujarat.
5.	Briefdetailsofgovernmentalregulatoryanyorapprovals required for the acquisition	No government approvals required
6.	Indicative time period for completion of the acquisition	Within 3 month
7.	Nature of consideration - whether cash considerationor share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares areacquired	Not exceeding INR 40 million
9.	Percentage of shareholding / control acquired and / ornumber of shares acauired;	Complete Control
10.	Brief background about the entity acquired in terms ofproducts/lineofbusinessacquired,dateofincorporation, history of last 3 years turnover, countryin which the acquired entity has presence and anyother significant information	M/s.BindishDiagnosticLaboratoryLLP provides range of pathology anddiagnostic tests/services through theirdiagnosticlaboratorysituatedinJamnagar in the state of Gujarat.Turnover:As mentioned in clause 1 above.

An nexu re-II

Sr.No.	Particulars in respect of the Event	EventDetails/ Information of the
1.	Name of the target entity, details in brief such as size,turnover etc.	ChanReDiagnosticServicesNAME:PrivateLimited(whichwillhousethebusinessofChanReDiagnosticsLaboratory)
		Turnover:Combined Turnover of ChanRe DiagnosticServicesPrivateLimitedandChanReDiagnostic Laboratory:
		FY 2017-18- Rs. 9.52 Cr.FY 2018-19- Rs. 10.35 Cr.FY 2019-20 - Rs. 11.51 Cr.
2.	Whether the acquisition would fall within related partytransaction(s) and whether the promoter/ promoter group/group companies have any interest in the entity beingacquired? If yes, nature of interest and details thereof andwhether the same is done at "arm's length";	No, the transactions are not related partytransactions.
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limitedto, disclosure of reasons for acquisition of target entity, ifits business is outside the main line of business of thelisted entity);	To strengthen the Company's presence inthe state of Karnataka
5.	Brief details of any governmental or regulatory approvalsrequired for the acquisition	No government approvals required
6.	Indicative time period for completion of the acquisition	Within 3 month
7.	Nature of consideration - whether cash consideration orshare swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares areacquired	Not exceeding INR 175 million
9.	Percentage of shareholding / control acquired and I ornumber of shares acquired;	Acquisitionof70%stakeinChanReDiaqnostic Services Private Limited.
10.	Brief background about the entity acquired in terms ofproducts/line of business acquired, date of incorporation,history of last 3 years turnover, country in which theacquired entity has presence and any other significantinformation	ChanReDiagnosticServicesPrivateLimited, incorporated on May 21, 2015, aCompany engaged in providing diagnosticservices in the state of KarnatakaTurnover: As mentioned in clause 1 above.